ArticleNature communications2020
CD73 on cancer-associated fibroblasts enhanced by the A
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
17.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 179 citations in OpenAlex.
- A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC).Oncoimmunology · 2026Article
- Metabolic reprogramming in cancer-associated fibroblasts: orchestrating the tumor immune microenvironment and response to immune checkpoint blockade.Experimental hematology & oncology · 2026Review
- A2BAR Antagonism Mitigates Pulmonary Inflammation and Fibrosis and Restores Macrophage M1/M2 Balance in Diabetic Rats.International journal of molecular sciences · 2026Article
- CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy.Nature communications · 2026Article
- Immunosuppressive Pathways in Cutaneous Melanoma: Functional Integration Between PD-1 and CD73 and Therapeutic Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Emerging Roles of Adenosine Metabolism in Astrocytes During Brain Injury.CNS neuroscience & therapeutics · 2026Review
- Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.Discover oncology · 2026Article
- Enhanced antitumor efficacy of combined targeting of adenosine ACancer immunology, immunotherapy : CII · 2026Article
- CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation.Journal for immunotherapy of cancer · 2026Article
- The CD73-adenosine axis in melanoma: from multidimensional regulation to precision immunotherapy.Frontiers in immunology · 2026Review
- Adenosine signaling in tumor immune escape: metabolic checkpoints, myeloid suppression, and combination immunotherapy.Frontiers in oncology · 2026Review
- Restoring adenosine balance in axial spondyloarthritis: a stage-specific framework for immune and structural modulation.Frontiers in immunology · 2026Review
- Integration of tumor microenvironment and metabolic signatures reveals TMPI-defined prognostic and immunotherapy-relevant phenotypes in breast cancer.Frontiers in pharmacology · 2026Article
- Ferroptosis meets cancer immunotherapy: Overcoming the crosstalk challenges through advanced drug delivery strategies.Acta pharmaceutica Sinica. B · 2025Review
- Metabolomic and transcriptomic profiling of HNSCC identifies AMIGO2 as a therapeutic target modulating tumor microenvironment.NPJ precision oncology · 2025Article
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- Role of metabolic reprogramming of cancer‑associated fibroblasts in tumor development and progression (Review).International journal of oncology · 2025Review
- Monod: model-based discovery and integration through fitting stochastic transcriptional dynamics to single-cell sequencing data.Nature methods · 2025Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Miao Yu *Department of Biochemistry and Molecular Biology, Cancer Immunology, Inflammation & Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0002-3614-1329
Gang Guo *Department of Biochemistry and Molecular Biology, Cancer Immunology, Inflammation & Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.
Lei HuangTranslational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.ORCID http://orcid.org/0000-0002-1996-944X
Libin DengInstitute of Translational Medicine, Nanchang University, Nanchang, 30000, Jiangxi, China.
Chang-Sheng ChangBioinformatics Shared Resource and Integrated Genomics, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0002-3879-6599
Bhagelu R AchyutDepartment of Biochemistry and Molecular Biology, Tumor Signaling & Angiogenesis, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.
Madison CanningSchool of Medicine, Augusta University, Augusta, GA, 30912, USA.
Ningchun XuFlow cytometry Core, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.
Ali S ArbabDepartment of Biochemistry and Molecular Biology, Tumor Signaling & Angiogenesis, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0003-2902-3671
Roni J BollagTumor Tissue and Serum Biorepository, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0003-4963-6619
Paulo C RodriguezDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
Andrew L MellorTranslational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Huidong ShiDepartment of Biochemistry and Molecular Biology, Molecular Biology & Biomarkers, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0003-1137-3390
David H MunnDepartment of Biochemistry and Molecular Biology, Cancer Immunology, Inflammation & Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA.
Yan CuiDepartment of Biochemistry and Molecular Biology, Cancer Immunology, Inflammation & Tolerance Program, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA. ycui@augusta.edu.ORCID http://orcid.org/0000-0002-2800-6039
Augusta University Health · USNewcastle University · GBAugusta University · USMoffitt Cancer Center · USNanchang University · CN
Funding
Reprogramming the TME for immunogenic antigen-presentationR01CA103320 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2024
$6.0MStress Pathways in Tumors Drive Global MDSC Activity and Survival through ChopR01CA184185 · NCI · LSU HEALTH SCIENCES CENTER · PI RODRIGUEZ, PAULO CESAR · 2015 to 2019
$1.8MPTEN, Tregs and MDSCs in the tumor microenvironmentR01CA211229 · NCI · AUGUSTA UNIVERSITY · PI MUNN, DAVID H. · 2017 to 2021
$1.7MP53 inactivation on MDSC development and tumor progressionR01CA169133 · NCI · LSU HEALTH SCIENCES CENTER · PI CUI, YAN · 2013 to 2017
$1.5MHigh Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600kCD73 expression on cancer-associated fibroblasts of Head and Neck Cancers shapes the immune landscapeR21DE028716 · NIDCR · AUGUSTA UNIVERSITY · PI CUI, YAN · 2019 to 2020
$421kNCI NIH HHS R01 CA103320NCI NIH HHS R01 CA169133NCI NIH HHS R01 CA211229NIDCR NIH HHS R21 DE028716NIH HHS S10 OD021805
Abstract
CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A
Indexed as
5'-NucleotidaseAdenosineAdenosine A2 Receptor AntagonistsAnimalsCancer-Associated FibroblastsCell Line, TumorColorectal NeoplasmsDisease ProgressionDrug SynergismHematopoietic Stem CellsHumansLymphocytes, Tumor-InfiltratingMice, Inbred C57BLModels, BiologicalNeutralization TestsReceptor, Adenosine A2B5'-NucleotidaseAdenosineAdenosine A2 Receptor AntagonistsReceptor, Adenosine A2B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.